Design Therapeutics (DSGN) Equity Average (2020 - 2026)

Design Therapeutics has disclosed Equity Average across 7 years of filings, most recently posting $215.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $215.3 million, down 8.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $215.3 million (down 8.4% YoY), and the FY2025 annual result was $227.3 million, down 12.54% from the prior year.
• Equity Average came in at $215.3 million for Q1 2026 at Design Therapeutics, up from $206.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $376.2 million in Q1 2022 to a low of $206.1 million in Q4 2025.
• The 5-year median for Equity Average is $273.6 million (2024), against an average of $279.2 million.
• Across the five-year window, Equity Average surged 89.68% in 2022 and dropped 19.65% in 2025, its largest moves.
• Design Therapeutics' Equity Average stood at $334.1 million in 2022, then dropped by 15.8% to $281.3 million in 2023, then dropped by 12.1% to $247.3 million in 2024, then slipped by 16.65% to $206.1 million in 2025, then rose by 4.45% to $215.3 million in 2026.
• The last three Equity Average figures came in at $215.3 million (Q1 2026), $206.1 million (Q4 2025), and $206.4 million (Q3 2025), per Business Quant data.